From Clinical to Benchside: <scp>Lacticaseibacillus</scp> and <scp>Faecalibacterium</scp> Are Positively Associated With Muscle Health and Alleviate Age‐Related Muscle Disorder

Chaoran Liu, Pui Yan Wong, Nilakshi Barua, Baoqi Li, Hei Yuet Wong, Ning Zhang, Simon Kwoon‐Ho Chow, Sunny H. Wong, Jun Yu, Margaret Ip, Wing‐Hoi Cheung, Gustavo Duque, Christoph Brochhausen, Joseph J.�y. Sung, Ronald Man Yeung WongAging 2025 · DOI

TL;DR

This study reveals a strong link between gut microbiota dysbiosis and sarcopenia, an age-related muscle disorder. By transplanting gut microbes from sarcopenic individuals into mice, researchers demonstrated that these microbes can induce muscle weakness. Conversely, specific probiotics, Lacticaseibacillus rhamnosus (LR) and Faecalibacterium prausnitzii (FP), improved muscle health in aged mice, primarily by enhancing mitochondrial function.

What Problem Does This Paper Address?

Sarcopenia, the age-related loss of muscle mass and strength, is a significant health concern leading to increased risks of falls, fractures, and mortality. Current treatments are limited, and the underlying causes are not fully understood. Emerging research suggests the gut microbiome plays a role in various physiological processes, including muscle health, through a "gut-muscle axis." However, the specific contribution of gut microbiota dysbiosis to sarcopenia and potential microbial interventions remain unclear. This paper aims to bridge this gap by investigating the gut microbiota's role in sarcopenia, establishing a causal link, and identifying specific probiotics for therapeutic intervention.

Methods

The study employed a multi-pronged approach:

  • Human Cohort Analysis: Gut microbiota composition and metabolites were compared between elderly individuals with and without sarcopenia using shotgun metagenomic sequencing and liquid chromatography-mass spectrometry (LC-MS).
  • Fecal Microbiota Transplantation (FMT): To establish causality, gut microbiota from human donors (sarcopenic and non-sarcopenic) were transplanted into antibiotic-treated recipient mice.
  • Probiotic Intervention in Aged Mice: Specific probiotics (Lacticaseibacillus rhamnosus (LR) and Faecalibacterium prausnitzii (FP)) and their combination were administered to aged mice to assess their therapeutic effects on muscle health.
  • Mechanistic Investigations: Transcriptomics (RNA-seq), protein analysis (Western blot), and various biochemical assays were used to elucidate the mechanisms by which probiotics exert their effects, focusing on mitochondrial function, muscle atrophy pathways, and gut barrier integrity.
  • Gut Microbiota and Immune Analysis: 16S rDNA sequencing was used to analyze gut microbiota changes post-intervention, and flow cytometry was employed to assess immune cell populations in the colon.

Datasets

The study utilized two primary datasets:

  • Human Participants: Stool samples from 51 older adults (categorized as sarcopenic or non-sarcopenic) and blood samples from 38 hip fracture patients (stratified by appendicular skeletal muscle mass index - ASMI).
  • Animal Models: Antibiotic-treated recipient mice for FMT experiments and aged male C57BL/6 mice for probiotic intervention studies.

No new benchmark datasets were introduced.

Key Insights and Ideas

  • Gut Microbiota as a Driver of Sarcopenia: The FMT experiments provided compelling evidence that gut microbiota from sarcopenic individuals can indeed induce muscle weakness in recipient mice, strongly suggesting gut dysbiosis is a pathogenic factor in sarcopenia.
  • Purine Metabolism as a Biomarker: The study identified purine levels as a potential biomarker to distinguish between individuals with and without sarcopenia, highlighting its role in the metabolic differences associated with the condition.
  • Mitochondrial Health is Key: The most significant finding regarding probiotic mechanisms is their ability to enhance muscle mitochondrial density, ATP content, and NAD+/NADH ratio. This points to mitochondrial dysfunction as a central player in age-related muscle decline and a prime target for probiotic intervention.
  • Probiotics Offer a Therapeutic Avenue: Lacticaseibacillus rhamnosus (LR) and Faecalibacterium prausnitzii (FP) demonstrated significant benefits in improving muscle mass, strength, and function in aged mice, offering a promising therapeutic strategy.
  • Gut Barrier and Immune Modulation: Beyond muscle benefits, these probiotics also improved gut barrier function and, notably, LR and the combination therapy modulated colon immune responses by reducing pro-inflammatory T cells.

Key Results

  • Elderly individuals with sarcopenia exhibited distinct gut microbiota compositions and metabolite profiles compared to non-sarcopenic individuals.
  • FMT from sarcopenic donors led to reduced muscle mass, strength, and myofiber cross-sectional area in recipient mice.
  • Lacticaseibacillus rhamnosus (LR) and Faecalibacterium prausnitzii (FP) administration improved muscle mass, grip strength, and tetanic force in aged mice.
  • Probiotic treatments enhanced muscle mitochondrial density, ATP content, and NAD+/NADH ratio.
  • Transcriptomic analysis revealed enrichment of pathways related to the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in probiotic-treated mice.
  • Probiotics improved gut barrier function proteins (e.g., E-cadherin, Occludin) and reduced pro-inflammatory cytokines in the colon.
  • LR and the combination therapy significantly reduced CD8+ IFNy+ T cells in the colon.

Limitations and Future Work

The authors acknowledge several limitations:

  • Circulating Metabolites: The study did not analyze circulating gut microbiota-derived metabolites.
  • Serum Biomarkers: Serum markers of gut barrier function were only assessed in hip fracture patients, potentially introducing bias. Future studies should compare these parameters in sarcopenic and non-sarcopenic individuals.
  • Antibiotic Use in FMT: The use of antibiotic-treated mice for FMT could have confounding effects on muscle health. Germ-free mice are suggested for future FMT studies.
  • Sex Differences: The probiotic intervention studies were conducted solely in male mice, and future research should investigate effects in female mice and humans.
  • Sarcopenic Mouse Model: The study did not utilize a sarcopenic mouse model with established muscle indicators, which could better mimic human sarcopenia.

Future work should focus on large-scale studies to accurately identify differential gut microbiota and metabolites, explore the therapeutic potential of LR and FP in human clinical trials, and investigate novel treatments targeting specific bacteria enriched in sarcopenia.

Summary updated

Abstract

Sarcopenia is an age-related muscle disorder that increases risks of adverse clinical outcomes, but its treatments are still limited. Gut microbiota is potentially associated with sarcopenia, and its role is still unclear. To investigate the role of gut microbiota in sarcopenia, we first compared gut microbiota and metabolites composition in old participants with or without sarcopenia. Fecal microbiota transplantation (FMT) from human donors to antibiotic-treated recipient mice was then performed. Specific probiotics and their mechanisms to treat aged mice were identified. Old people with sarcopenia had different microbial composition and metabolites, including Paraprevotella, Lachnospira, short-chain fatty acids, and purine. After FMT, mice receiving microbes from people with sarcopenia displayed lower muscle mass and strength compared with those receiving microbes from non-sarcopenic donors. Lacticaseibacillus rhamnosus (LR) and Faecalibacterium prausnitzii (FP) were positively related to muscle health of old people, and enhanced muscle mass and function of aged mice. Transcriptomics showed that genes related to tricarboxylic acid cycle (TCA) were enriched after treatments. Metabolic analysis showed increased substrates of TCA cycle in both LR and FP supernatants. Muscle mitochondria density, ATP content, NAD<sup>+</sup>/NADH, mitochondrial dynamics and biogenesis proteins, as well as colon tight junction proteins of aged mice were improved by both probiotics. LR and the combination of two probiotics also benefit intestinal immune health by reducing CD8<sup>+</sup> IFNγ<sup>+</sup> T cells. Gut microbiota dysbiosis is a pathogenesis of sarcopenia, and muscle-related probiotics could alleviate age-related muscle disorders mainly through mitochondria improvement. Further clinical translation is warranted.
BibTeX
@inproceedings{liu2025from,
  author = {Chaoran Liu and Pui Yan Wong and Nilakshi Barua and Baoqi Li and Hei Yuet Wong and Ning Zhang and Simon Kwoon‐Ho Chow and Sunny H. Wong and Jun Yu and Margaret Ip and Wing‐Hoi Cheung and Gustavo Duque and Christoph Brochhausen and Joseph J.�Y. Sung and Ronald Man Yeung Wong},
  title = {{From Clinical to Benchside: <scp><i>Lacticaseibacillus</i></scp> and <scp><i>Faecalibacterium</i></scp> Are Positively Associated With Muscle Health and Alleviate Age‐Related Muscle Disorder}},
  booktitle = {Aging},
  year = {2025},
  doi = {10.1111/acel.14485},
}
Figure